Bristol-Myers Squibb is investing approximately $250 million to expand its large-scale biologics manufacturing facility in Devens, MA. The expansion will add biologics development and clinical trial manufacturing capabilities, and an additional 350 employees over time. Work on the expansion is expected to be completed in 2015.
 
Two new buildings on the 89-acre Devens campus will be dedicated to process development for early production of investigational biologics and clinical manufacturing to support clinical trials. Together, the two buildings will add approximately 200,000 sq. ft. of lab and office space. Previously the facility focused solely on large-scale, bulk biologics manufacturing.
 
“Biologics are increasingly important in the treatment of serious diseases and are a growing part of our company’s pipeline of potential new therapies,” said Lou Schmukler, president, Global Manufacturing & Supply at BMS. “This initiative is designed to accelerate the development of new biologics medicines through the closer alignment of biologics R&D and manufacturing.”